// App-Quantinova.ai

AB0360 : EFFICACY AND SAFETY OF THE PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST CR6086 ADDED TO METHOTREXATE IN DMARD-NAÏVE EARLY RA PATIENTS: A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Researchers

Presenter

  • K. Pavelka

Principal Investigators

  • I. D. Delina

  • M. Mazur

  • M. Damato

  • G. Giacovelli

  • F. Girolami

  • M. Krogulec

  • R. stgrd

  • A. R. Bihlet

  • O. Kubassova

  • L. Rovati

  • P. C. Taylor

Medical Centers

  • Institute of Rheumatology, Prague, Czech Republic

  • Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria

  • Nicolae Testemitanu State Univ. of Med. and Pharm., Chisinau, Moldova, Republic of

  • Rottapharm Biotech, Monza, Italy

  • NZOZ Lecznica MAK-MED, Nadarzyn, Poland

  • Silkeborg Hospital, Silkeborg, Denmark

  • Nordic Bioscience, Herlev, Denmark

  • Image Analysis, London, United Kingdom

  • Univ. of Milano, Milano, Italy

  • Botnar Research Center, Univ. of Oxford, Oxford, United Kingdom

Locations

  • Czech Republic

  • Bulgaria

  • Republic of South Korea

  • Italy

  • Poland

  • Denmark

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • 3β-hydroxysterol Δ24-reductase

  • Albumin/creatinine

Drug/Treatment

  • Prostaglandin

  • Methotrexate

  • CR6086

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • NCT03163966

Sponsors

  • Celgene

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved